Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy

Achim Temme^{1

2}, Marc Schmitz^{3

2}

Affiliations

¹ Department of Neurosurgery, Section Experimental Neurosurgery & Tumor Immunology, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
² German Cancer Consortium (DKTK), Dresden, Germany, & German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany.

Editorial

Achim Temme et al. Immunotherapy. 2016 Sep.

. 2016 Sep;8(9):983-6.

doi: 10.2217/imt-2016-0072.

Achim Temme^{1

2}, Marc Schmitz^{3

2}

¹ Department of Neurosurgery, Section Experimental Neurosurgery & Tumor Immunology, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
² German Cancer Consortium (DKTK), Dresden, Germany, & German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany.

No abstract available

Keywords: chimeric antigen receptor; genetic engineering; primary natural killer cells; tumor immunotherapy.

Publication types